Sustained co-delivery of 5-fluorouracil and cis-platinum via biodegradable thermo-sensitive hydrogel for intraoperative synergistic combination chemotherapy of gastric cancer
Source abstract
Abstract
Gastric cancer is the fifth most common cancer and the third leading cause of cancer death worldwide, posing a severe threat to human health. Surgical resection remains the most preferred option for gastric cancer treatment. However, for advanced gastric cancer, the curative effect of surgical resection is usually limited by the local recurrence, peritoneal carcinomatosis, or distal metastasis. Intraoperative chemotherapy is an attractive in situ adjuvant treatment strategy to reduce the recurrence and metastasis after surgical resection. Here, we designed a 5-fluorouracil (5-FU) and cis-platinum (DDP) co-delivery system based on a biodegradable temperature-sensitive hydrogel (PDLLA-PEG-PDLLA, PLEL) for intraoperative adjuvant combination chemotherapy of gastric cancer. This 5-FU + DDP/PLEL hydrogel system characterized by a special sol-gel phase transition in response to physiological temperature and presented sustained drug release in vitro and in vivo. A strong synergistic cell proliferation inhibition and apoptosis promotion of 5-FU + DDP/PLEL were observed against gastric cancer MKN45-luc cells. After intraperitoneal injection, the dual-drug loaded hydrogel formulation showed superior anti-tumor effects than the single-drug carrying hydrogels and combination of free 5-FU and DDP on the gastric cancer peritoneal carcinomatosis model. The use of hydrogel for dual-drug delivery had benefited to fewer side effects as well. What's more, we established a mouse model for postsurgical residual tumors and peritoneal carcinomatosis of gastric cancer, in which the intraoperative administration of 5-FU + DDP/PLEL also remarkably inhibited the local recurrence of the orthotopic tumors and the growth of the abdominal metastatic tumors, resulting in an extended lifetime. Hence, this developed dual-drug loaded hydrogel system has great potential in the intraoperative chemotherapy of gastric cancer, that suggests a clinically-relevant and valuable option for postsurgical management of gastric cancer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Intraperitoneal and Appendiceal Malignancies · Gastric Cancer Management and Outcomes · Gastrointestinal Tumor Research and Treatment
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (51)
Show source-provided references
1. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA10.3322/caac.21660 ↗
2. Staging, stage migration, and patterns of spread in gastric cancer10.1053/srao.2002.30816 ↗
3. An overview of acute gastrointestinal side effects of systemic anti-cancer therapy and their management
4. Radiotherapy side effects: integrating a survivorship clinical lens to better serve patients10.3747/co.27.6233 ↗
5. The use of intraperitoneal chemotherapy for gastric malignancies10.1080/14737140.2019.1671189 ↗
6. Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the inpact study, a randomized controlled trial10.1007/s10120-016-0598-0 ↗
7. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (cyto-chip study): a propensity score analysis10.1200/JCO.18.01688 ↗
8. Hyperthermic intraperitoneal chemotherapy (hipec) in combined treatment of locally advanced and intraperitonealy disseminated gastric cancer: a retrospective cooperative central-eastern european study10.1002/cam4.2204 ↗
9. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure10.1093/jnci/89.7.480 ↗
10. Hyperthermic intraperitoneal chemotherapy (hipec) for gynecological cancer10.1111/jog.14391 ↗
11. Intraperitoneal chemotherapy using fluorouracil implants combined with radical resection and postoperative adjuvant chemotherapy for stage iii gastric cancer: a multi-center, randomized, open-label, controlled clinical study
12. Retrospective cohort study of intraoperative administration of sustained-release 5-fluorouracil implants in advanced gastric cancer patients10.3389/fphar.2021.659258 ↗
13. Clinical research of intraperitoneal implantation of sustained-release 5-fluorouracil in advanced colorectal cancer10.1186/s12957-015-0737-9 ↗
14. Antitumor activity of thermosensitive hydrogels packaging gambogic acid nanoparticles and tumor-penetrating peptide irgd against gastric cancer10.2147/IJN.S231448 ↗
15. Novel “carrier-free” nanofiber codelivery systems with the synergistic antitumor effect of paclitaxel and tetrandrine through the enhancement of mitochondrial apoptosis10.1021/acsami.9b17363 ↗
16. Superior antitumor efficacy of ifn-α2b-incorporated photo-cross-linked hydrogels combined with t cell transfer and low-dose irradiation against gastric cancer10.2147/IJN.S249174 ↗
17. Sustained release of lipophilic gemcitabine from an injectable polymeric hydrogel for synergistically enhancing tumor chemoradiotherapy10.1016/j.cej.2020.125320 ↗
18. Docetaxel-loaded thermoresponsive conjugated linoleic acid-incorporated poloxamer hydrogel for the suppression of peritoneal metastasis of gastric cancer10.1016/j.biomaterials.2012.10.077 ↗
19. Injectable hydrogel-based drug delivery systems for local cancer therapy10.1016/j.drudis.2016.07.006 ↗
20. Sustained release of nitric oxide and cascade generation of reactive nitrogen/oxygen species via an injectable hydrogel for tumor synergistic therapy
21. Injectable and thermosensitive hydrogels mediating a universal macromolecular contrast agent with radiopacity for noninvasive imaging of deep tissues
22. Polysaccharide and polypeptide based injectable thermo-sensitive hydrogels for local biomedical applications10.1016/j.ijbiomac.2019.04.131 ↗
23. Camptothecin@hmsns/thermosensitive hydrogel composite for applications in preventing local breast cancer recurrence10.1016/j.cclet.2018.10.004 ↗
24. Injectable hydrogels for the sustained delivery of a her2-targeted antibody for preventing local relapse of her2+ breast cancer after breast-conserving surgery10.7150/thno.36514 ↗
25. Peg-based thermosensitive and biodegradable hydrogels10.1016/j.actbio.2021.04.009 ↗
26. Improvement of anti-cancer drug efficacy via thermosensitive hydrogel in peritoneal carcinomatosis in gastric cancer10.18632/oncotarget.22312 ↗
27. Therapy for gastric cancer with peritoneal metastasis using injectable albumin hydrogel hybridized with paclitaxel-loaded red blood cell membrane nanoparticles10.1021/acsbiomaterials.8b01557 ↗
28. Advanced gastric cancer: current treatment landscape and future perspectives10.3748/wjg.v22.i8.2403 ↗
29. First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer10.1007/s10120-011-0056-y ↗
30. Metabolism of pyrimidine analogues and their nucleosides10.1016/0163-7258(90)90080-L ↗
31. 5-fluorouracil (5-fu) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition10.1016/j.biopha.2021.111285 ↗
32. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma
33. Chemotherapy for advanced gastric cancer10.1002/14651858.CD004064.pub2 ↗
34. Effects of intermittent 5-fluorouracil and low-dose cisplatin therapy on advanced and recurrent gastric cancer
35. Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study10.1186/s40880-018-0292-1 ↗
36. Oral fluoropyrimidine versus intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: meta-analysis10.1111/jgh.13845 ↗
37. Synthesis, characterization and application of reversible pdlla-peg-pdlla copolymer thermogels in vitro and in vivo
38. Sustained co-delivery of gemcitabine and cis-platinum via biodegradable thermo-sensitive hydrogel for synergistic combination therapy of pancreatic cancer10.1007/s12274-019-2342-7 ↗
39. Multifunctional nanoparticle loaded injectable thermoresponsive hydrogel as nir controlled release platform for local photothermal immunotherapy to prevent breast cancer postoperative recurrence and metastases10.1002/adfm.202001059 ↗
40. Dietary isoflavone daidzein synergizes centchroman action via induction of apoptosis and inhibition of pi3k/akt pathway in mcf-7/mda mb-231 human breast cancer cells10.1016/j.phymed.2018.01.007 ↗
41. Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model10.1016/j.jconrel.2014.03.016 ↗
42. Novel thymopentin release systems prepared from bioresorbable pla–peg–pla hydrogels10.1016/j.ijpharm.2009.10.045 ↗
43. In-vitro effect of a combination of 5-fluorouracil (5-fu) and cisplatin (cddp) on human gastric cancer cell lines: timing of cisplatin treatment10.1007/s101200200006 ↗
44. Feasibility study on protracted infusional 5-fluorouracil and consecutive low-dose cisplatin for advanced gastric cancer10.1159/000227537 ↗
45. Nanoparticles with precise ratiometric co-loading and co-delivery of gemcitabine monophosphate and cisplatin for treatment of bladder cancer10.1002/adfm.201401076 ↗
46. Use of a combination of computed tomography and endoscopy to assess the response to 5-fluorouracil/cisplatin and predict survival in gastric cancer10.1007/s00535-005-1759-9 ↗
47. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the ffcd randomized phase iii trial (8801)10.1093/annonc/mdi270 ↗
48. Phase iii trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie10.1200/JCO.2007.13.9378 ↗
49. Prediction of 5-fluorouracil and cisplatin synergism for advanced gastrointestinal cancers using a collagen gel droplet embedded culture10.1007/s00595-003-2569-4 ↗
50. Analysis of the in vitro synergistic effect of 5-fluorouracil and cisplatin on cervical carcinoma cells10.1136/ijgc-00009577-200605000-00056 ↗
51. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies10.1038/sj.ki.5002786 ↗